Achieve Life Sciences, Inc.
ACHV
Health Care
1
exclusion reason
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company whose lead investigational drug, cytisinicline, is being developed as a smoking cessation treatment. The company's preclinical and clinical development programs rely on animal testing as a standard component of pharmaceutical research and regulatory compliance. In its 2022 Annual Report on Form 10-K, Achieve Life Sciences describes its drug candidate as having been "evaluated in over 40 clinical and non-clinical studies," a category which inherently includes animal testing to assess pharmacology, toxicology, and safety prior to human trials. The company's business model is predicated on advancing cytisinicline through the FDA approval pathway, which mandates animal data as a foundational requirement for Investigational New Drug (IND) applications and subsequent clinical trials.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.